Nab-paclitaxel as second-line treatment in advanced gastric cancer: a multicenter phase II study of the Hellenic Oncology Research Group | Zendy

AI Assistant Blog Pricing

Nab-paclitaxel as second-line treatment in advanced gastric cancer: a multicenter phase II study of the Hellenic Oncology Research Group

Details

The content you want is available to Zendy users.Already have an account? Click here. to sign in.